SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Celator Pharmaceuticals, Inc. Enrolls First Patient in Its Phase 3 Study of CPX-351 in Untreated High-Risk Acute Myeloid Leukemia